Burning Rock Provides Second Quarter 2022 Business Updates and Schedules Earnings Release on August 31, 2022
August 04 2022 - 8:10AM
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or
“Burning Rock”), a company focused on the application of next
generation sequencing (NGS) technology in the field of precision
oncology, today announced that it plans to release its unaudited
financial results for the second quarter of 2022 before the U.S.
market opens on August 31, 2022. Following the release, company
management will host a conference call at 8:30 a.m. ET (8:30 p.m.
Hong Kong time) on the same day to discuss its financial results
for the second quarter of 2022.
While the Company has not completed preparation of
its financial statements for the second quarter of 2022, it expects
to report a moderate growth in revenues year-over-year, driven by
new product launches and continued growth of its pharma service
revenues, offsetting the negative impact of COVID-19 related
lockdowns which severely impacted its business volumes in the
affected regions.
Please register in advance of the conference using
the link provided below and dial in 15 minutes prior to the call,
using participant dial-in numbers and unique registrant ID which
would be provided upon registering.
PRE-REGISTER LINK:
https://register.vevent.com/register/BI1f6043e15b804286b8c6f5db40d78456.
Additionally, a live and archived webcast of the
conference call will also be available on the company’s investor
relations website at http://ir.brbiotech.com or through link
https://edge.media-server.com/mmc/p/57gam4s5.
A replay of the webcast will be available for 12
months via the same link above.
Please visit the Company’s investor relations
website at
https://ir.brbiotech.com/news-events/news-releases on August
31, 2022 to view the earnings release prior to the conference
call.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR),
whose mission is to Guard Life via Science, focuses on the
application of next generation sequencing (NGS) technology in the
field of precision oncology. Its business consists of i) NGS-based
therapy selection testing for late-stage cancer patients, and ii)
NGS-based cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please
visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements constitute “forward-looking”
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
“will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates,” “target,” “confident” and similar
statements. Burning Rock may also make written or oral
forward-looking statements in its periodic reports to the SEC, in
its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Statements that are not
historical facts, including statements about Burning Rock’s beliefs
and expectations, are forward-looking statements. Such statements
are based upon management’s current expectations and current market
and operating conditions, and relate to events that involve known
or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock’s
control. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jul 2023 to Jul 2024